Genovation Health, Thermo Fisher Scientific, and XYGene Launch Strategic Co-Marketing Agreement to Expand Access to Integrated Genomic Solutions
Partnership integrates Axiom™ microarray data with real-time clinical decision support to advance precision medicine at the point of care.
This collaboration leverages the strengths of each company to simplify the integration of Predictive Genomic data generated from Applied Biosystems™ Axiom™ microarrays
LAS VEGAS, NV, October 14, 2025 /24-7PressRelease/ — Genovation Health, a leader in real-time clinical decision support, announced today a multi-year strategic co-marketing agreement with Thermo Fisher Scientific (NYSE: TMO), the world leader in serving science, and XYGene, a genomic workflow integrator. The partnership is designed to streamline test ordering, speed up delivery of genomic results, and improve the clinical implementation of advanced diagnostics and pharmacogenomics.
“The power of genomic medicine is only realized if it can work for the clinician, as they help their patients,” said Dr. Howard McLeod, Precision Medicine expert and cofounder of Genovation Health.
Today’s clinicians increasingly rely on pharmacogenetic and genomic testing to guide care, but current workflows often introduce delays, fragmented data, and integration challenges. “This agreement validates the foundation we’ve built—a scalable, evergreen platform that delivers precision at the point of care,” said Christopher Duey, CEO of Genovation Health. “Teaming with Thermo Fisher and XYGene expands our ability to deliver real-time insights that improve safety, speed, and personalization in Predictive Genomics.”
“Healthcare providers face challenges with implementing end-to-end solutions within enterprise healthcare systems,” noted Shantanu Kaushikkar, Director, Global Commercial Leader and Head of Business Development at Thermo Fisher Scientific. “This collaboration leverages the strengths of each company to simplify the integration of Predictive Genomic data generated from Applied Biosystems™ Axiom™ microarrays with enterprise clinical decision support systems and reporting processes to develop an end-to-end solution. Our customers will be able to rapidly derive meaningful insights from multi-omic data and lower healthcare costs”
“Genovation’s real-time clinical intelligence combined with Thermo Fisher’s trusted lab platforms creates a transformative offering,” said Patrick Geren, CEO of XYGene. “Together, we’re empowering providers and labs with tools that improve outcomes, reduce friction, and accelerate delivery of personalized care.”
FlexHealth, a precision medicine partner, shared: “Partnering with Genovation, Thermo Fisher, and XYGene has significantly enhanced our ability to deliver vital genomic insights. Their collaboration improves the patient journey and enables more informed decisions.”
Key elements of the collaboration include:
• Coordinated commercial strategy and go-to-market alignment.
• Integrated support systems for education, microarrays, and product deployment.
• Comprehensive bioinformatics for tertiary analysis and reporting.
• Standardized processes to improve efficiency and turnaround time.
• Automation to reduce error and increase throughput.
• Joint marketing campaigns to educate and engage the market.
• Stringent data protection aligned with regional privacy laws.
About Genovation Health
Genovation Health delivers real-time clinical decision support that integrates genomics, pharmacology, and patient data into EHR and mobile systems. The platform helps providers make safer, faster, and more personalized decisions while supporting labs, health systems, and employer health programs.
About XYGene
XYGene offers a decision-support platform for genomic workflows, integrating with LIS and EHRs. The platform supports infectious disease panels, rare disease diagnostics, and pharmacogenomics while improving speed and reducing diagnostic friction.
# # #
